NDC product
carbamazepine
NDC 16714-063 · Northstar Rx LLC
Key facts
| Product NDC | 16714-063 |
|---|---|
| Proprietary name | carbamazepine |
| Nonproprietary name | carbamazepine |
| Substances | CARBAMAZEPINE |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Northstar Rx LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA205571 |
| Pharmacologic classes | Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE] and 1 more |
| Marketing start | Feb 1, 2021 |
| Marketing end | Jan 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory